Germany’s Merck KGaA has announced that it anticipates no sales of its multiple sclerosis treatment Mavenclad in the U.S. after March due to an expected influx of generic competitors. This decision follows the company’s unsuccessful efforts to defend its market position against generic entrants, which is a significant shift given Mavenclad’s previous role as a revenue driver for the firm.
The context surrounding this development is critical; Merck KGaA had previously reported solid sales growth in 2025, but the looming threat of generics poses a substantial challenge to its profitability. The company’s reliance on Mavenclad as a key product in its portfolio highlights the risks associated with patent expiration and market competition in the pharmaceutical landscape.
The implication of this situation extends beyond Merck KGaA, as it underscores the broader trend of increasing generic penetration in the market. This shift may compel other pharmaceutical companies to reevaluate their strategies regarding patent protections and market positioning, particularly for high-revenue products facing imminent generic competition.
Open the full market picture for your next decision →
